Patents by Inventor Genoveffa Franchini
Genoveffa Franchini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210340188Abstract: Embodiments of recombinant HIV-1 gp120 proteins that contain a V1 deletion are disclosed. Also provided are gp140, gp145, and gp160 proteins containing the V1 deletion, as well as HIV-1 Env ectodomain trimers containing protomers containing the V1 deletion. Nucleic acid molecules encoding these proteins are also provided. In several embodiments, the disclosed recombinant HIV-1 proteins and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject, for example, to treat or prevent an HIV-1 infection in the subject.Type: ApplicationFiled: October 21, 2019Publication date: November 4, 2021Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, New York UniversityInventors: Genoveffa Franchini, Timothy Cardozo, Manuel Becerra-Flores, Isabela Silva de Castro, Giacomo Gorini, Massimiliano Bissa
-
Patent number: 10398772Abstract: Compositions including a therapeutically effective amount of an HIV immunogen in combination with an agent that stimulates the Ras pathway, wherein the agent is not an aluminum salt, are disclosed. Methods are also disclosed for inducing an immune response to HIV, and/or to inhibit or treat HIV infection, in a subject, using an HIV immunogen and an agent that stimulates the Ras pathway. Methods also are disclosed for determining if an immunogenic composition will induce a protective response, and/or to determine if an immunogenic composition is of use to prevent or treat an HIV infection. The methods including determining if the immunogenic composition increases the level of one or more components of the Ras signaling pathway.Type: GrantFiled: January 8, 2015Date of Patent: September 3, 2019Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Oregon Health & Science UniversityInventors: Genoveffa Franchini, Rafick-Pierre Sekaly, Slim Fourati, Mark Cameron, Monica Vaccari, Luca Schifanella, Shari Gordon, Melvin Doster, Namal Malimbada Liyanage
-
Publication number: 20160331830Abstract: Compositions including a therapeutically effective amount of an HIV immunogen in combination with an agent that stimulates the Ras pathway, wherein the agent is not an aluminum salt, are disclosed. Methods are also disclosed for inducing an immune response to HIV, and/or to inhibit or treat HIV infection, in a subject, using an HIV immunogen and an agent that stimulates the Ras pathway. Methods also are disclosed for determining if an immunogenic composition will induce a protective response, and/or to determine if an immunogenic composition is of use to prevent or treat an HIV infection. The methods including determining if the immunogenic composition increases the level of one or more components of the Ras signaling pathway.Type: ApplicationFiled: January 8, 2015Publication date: November 17, 2016Applicants: THE UNITED STATES OF AMERICA,as represented by the Secretary,Department of Health and Human Services, OREGON HEALTH & SCIENCE UNIVERSITYInventors: Genoveffa Franchini, Rafick-Pierre Sekaly, Slim Fourati, Mark Cameron, Monica Vaccari, Luca Schifanella, Shari Gordon, Melvin Doster, Namal Malimbada Liyanage
-
Publication number: 20140286991Abstract: Compositions are provided comprising heat shock protein, immunoglobulins and retroviral antigens to induce systemic and mucosal immunity to infection from retroviruses such as Human Immunodeficiency Virus (HIV). Methods of treatment provided comprise administration of the compositions, which boost the immune systems response to the retroviral antigens or immunogens.Type: ApplicationFiled: February 23, 2012Publication date: September 25, 2014Applicant: UNIVERSITY OF MIAMIInventors: Eckhard R. Podack, Natasa Strbo, Genoveffa Franchini, Monica Vaccari
-
Publication number: 20110081368Abstract: The invention described here entails a protein vaccine against poxviruses which contains at least two purified recombinant monkeypox virus proteins or peptides. The proteins or peptides are encoded by the open reading frames of the monkeypox ortholog genes M1R, A35R, A29L B6R, and orthologs of these proteins or peptides having 90% identity. The invention also entails a vaccine protocol against poxvirus whereby a vaccine is vaccinated with a first vaccine made up of a nucleic acid vaccine of three or more poxvirus virus genes, and subsequently vaccinated with at least one other booster vaccine made up of two or more poxvirus virus proteins.Type: ApplicationFiled: May 28, 2010Publication date: April 7, 2011Inventors: Jay W. Hooper, Genoveffa Franchini
-
Publication number: 20100291037Abstract: This invention relates to improved methods of inducing an immune response for the prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in conjunction with a recombinant viral vaccine, e.g., a poxvirus vaccine, to potentiate and broaden the immune response. The present invention further provides a particularly effective vaccine regimen comprising a DNA vaccine used in combination with a poxvirus virus, especially NYVAC or ALVAC.Type: ApplicationFiled: July 28, 2010Publication date: November 18, 2010Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Genoveffa Franchini, Zdenek Hel, George Pavlakis, James Tartaglia
-
Patent number: 7790182Abstract: The invention described here entails a protein vaccine against poxviruses which contains at least two purified recombinant monkeypox virus proteins or peptides. The proteins or peptides are encoded by the open reading frames of the monkeypox ortholog genes M1R, A35R, A29L B6R, and orthologs of these proteins or peptides having 90% identity. The invention also entails a vaccine protocol against poxvirus whereby a vaccine is vaccinated with a first vaccine made up of a nucleic acid vaccine of three or more poxvirus virus genes, and subsequently vaccinated with at least one other booster vaccine made up of two or more poxvirus virus proteins.Type: GrantFiled: September 20, 2006Date of Patent: September 7, 2010Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Jay W. Hooper, Genoveffa Franchini
-
Patent number: 7771729Abstract: This invention relates to improved methods of inducing an immune response for the prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in conjunction with a recombinant viral vaccine, e.g., a poxvirus vaccine, to potentiate and broaden the immune response. The present invention further provides a particularly effective vaccine regimen comprising a DNA vaccine used in combination with a poxvirus virus, especially NYVAC or ALVAC.Type: GrantFiled: July 5, 2006Date of Patent: August 10, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Genoveffa Franchini, Zdenek Hel, George Pavlakis, James Tartaglia
-
Publication number: 20100196491Abstract: The invention described here entails a protein vaccine against poxviruses which contains at least two purified recombinant monkeypox virus proteins or peptides. The proteins or peptides are encoded by the open reading frames of the monkeypox ortholog genes M1R, A35R, A29L B6R, and orthologs of these proteins or peptides having 90% identity. The invention also entails a vaccine protocol against poxvirus whereby a vaccine is vaccinated with a first vaccine made up of a nucleic acid vaccine of three or more poxvirus virus genes, and subsequently vaccinated with at least one other booster vaccine made up of two or more poxvirus virus proteins.Type: ApplicationFiled: September 20, 2006Publication date: August 5, 2010Inventors: Jay W. Hooper, Genoveffa Franchini
-
Publication number: 20080188640Abstract: Attenuated recombinant viruses containing DNA encoding an immunodeficiency virus and/or CTL antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: HIV1gag(+pro) (IIIB), gp120(MN) (+transmembrane), nef (BRU)CTL, pol(IIIB)CTL, ELDKWA or LDKW epitopes, preferably HIV1gag(+pro) (IIIB), gp120(MN) (+transmembrane), two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL epitopes; or two ELDKWA in gp120 V3 or another region or in gp160. The two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL epitopes are preferably CTL1, CTL2, pol1, pol2 and pol3. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses.Type: ApplicationFiled: August 8, 2007Publication date: August 7, 2008Inventors: Enzo Paoletti, James Tartaglia, William I. Cox, Robert Gallo, Genoveffa Franchini
-
Publication number: 20060240042Abstract: This invention relates to improved methods of inducing an immune response for the prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in conjunction with a recombinant viral vaccine, e.g., a poxvirus vaccine, to potentiate and broaden the immune response. The present invention further provides a particularly effective vaccine regimen comprising a DNA vaccine used in combination with a poxvirus virus, especially NYVAC or ALVAC.Type: ApplicationFiled: July 5, 2006Publication date: October 26, 2006Inventors: Genoveffa Franchini, Zdenek Hel, George Pavlakis, James Tartaglia
-
Publication number: 20060205070Abstract: The disclosure encompasses p28TEV polypeptide, polynucleotides, variants, and antagonists. p28TEV polypeptides and/or polynucleotides are useful in immunogenic compositions. p28TEV polypeptide antagonists include antagonist antibodies, antisense molecules or siRNA molecules. The antagonists and composition of the disclosure can be administered alone or in combination with other agents useful in the treatment of HIV infection, SIV infection, AIDS, or AIDS-related complex (ARC), including nucleoside, non-nucleoside, and/or reverse transcriptase inhibitors.Type: ApplicationFiled: February 27, 2006Publication date: September 14, 2006Applicant: The Government of the USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Miroslav Dundr, Genoveffa Franchini, Jake Fullen
-
Patent number: 7094408Abstract: This invention relates to improved methods of inducing an immune response for the prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in conjunction with a recombinant viral vaccine, e.g., a poxvirus vaccine, to potentiate and broaden the immune response. The present invention further provides a particularly effective vaccine regimen comprising a DNA vaccine used in combination with a poxvirus virus, especially NYVAC or ALVAC.Type: GrantFiled: April 30, 2001Date of Patent: August 22, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Genoveffa Franchini, Zdenek Hel, George Pavlakis
-
Publication number: 20060094006Abstract: This invention relates to an improved method of maintaining an immuno-protective response in persons infected with a retrovirus during early infection or after highly active anti-retroviral therapy.Type: ApplicationFiled: May 1, 2003Publication date: May 4, 2006Inventors: Genoveffa Franchini, James Tartaglia
-
Publication number: 20050019752Abstract: This invention provides novel HIV antigens comprising chimeric rev, tat, and nef for use in inducing an immune response. The novel antigens can be used as vaccines to prevent and/or attenuate HIV infection.Type: ApplicationFiled: November 15, 2002Publication date: January 27, 2005Inventors: Genoveffa Franchini, Zdenek Hel, James Tartaglia
-
Publication number: 20040033237Abstract: This invention relates to improved methods of inducing an immune response for the prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in conjunction with a recombinant viral vaccine, e.g., a poxvirus vaccine, to potentiate and broaden the immune response. The present invention further provides a particularly effective vaccine regimen comprising a DNA vaccine used in combination with a poxvirus virus, especially NYVAC or ALVAC.Type: ApplicationFiled: October 25, 2002Publication date: February 19, 2004Inventors: Genoveffa Franchini, Zdenek Hel, George Pavlakis
-
Publication number: 20030223987Abstract: Attenuated recombinant viruses containing DNA encoding an immunodeficiency virus and/or CTL antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: HIV1gag(+pro)(IIIB), gp120(MN)(+transmembrane), nef(BRU)CTL, pol(IIIB)CTL, ELDKWA or LDKW epitopes, preferably HIV1gag(+pro)(IIIB), gp120(MN) (+transmembrane), two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL epitopes; or two ELDKWA in gp120 V3 or another region or in gp160. The two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL epitopes are preferably CTL1, CTL2, pol1, pol2 and pol3. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses.Type: ApplicationFiled: May 20, 2003Publication date: December 4, 2003Inventors: Enzo Paoletti, James Tartaglia, William I. Cox, Robert Gallo, Genoveffa Franchini
-
Patent number: 6596279Abstract: Attenuated recombinant viruses containing DNA encoding an immunodeficiency virus and/or CTL antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: HIV1gag(+pro)(IIIB), gp120(MN)(+transmembrane), nef(BRU)CTL, pol(IIIB)CTL, ELDKWA or LDKW epitopes, preferably HIV1gag(+pro)(IIIB), gp120(MN) (+transmembrane), two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL etpitopes; or two ELDKWA in gp120 V3 or another region or in gp160. The two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL epitopes are preferably CTL1, CTL2, pol1, pol2 and pol3. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses.Type: GrantFiled: August 14, 1998Date of Patent: July 22, 2003Assignee: Virogenetics CorporationInventors: Enzo Paoletti, James Tartaglia, William I. Cox, Robert Gallo, Genoveffa Franchini
-
Patent number: 5869313Abstract: The present invention relates to the HIV-1 strains MN-ST1 and BA-L which are typical United States HIV-1 isotypes. The present invention relates to DNA segments encoding the envelope protein of MN-ST1 or BA-L, to DNA constructs containing such DNA segments and to host cells transformed with such constructs. The viral isolates and envelope proteins of the present invention are of value for use in vaccines and bioassays for the detection of HIV-1 infection in biological samples, such as blood bank samples.Type: GrantFiled: May 14, 1996Date of Patent: February 9, 1999Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Marvin S. Reitz, Jr., Genoveffa Franchini, Phillip D. Markham, Robert C. Gallo, Franco C. Lori, Mikulas Popovic, Suzanne Gartner
-
Patent number: 5576000Abstract: The present invention relates to the HIV-1 strains MN-ST1 and BA-L which are typical United States HIV-1 isotypes. The present invention relates to DNA segments encoding the envelope protein of MN-ST 1 or BA-L, to DNA constructs containing such DNA segments and to host cells transformed with such constructs. The viral isolates and envelope proteins of the present invention are of value for use in vaccines and bioassays for the detection of HIV-1 infection in biological samples, such as blood bank samples.Type: GrantFiled: February 15, 1995Date of Patent: November 19, 1996Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Marvin S. Reitz, Jr., Genoveffa Franchini, Phillip D. Markham, Robert C. Gallo, Franco C. Lori, Mikulas Popovic, Suzanne Gartner